JP2009530306A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530306A5
JP2009530306A5 JP2009500525A JP2009500525A JP2009530306A5 JP 2009530306 A5 JP2009530306 A5 JP 2009530306A5 JP 2009500525 A JP2009500525 A JP 2009500525A JP 2009500525 A JP2009500525 A JP 2009500525A JP 2009530306 A5 JP2009530306 A5 JP 2009530306A5
Authority
JP
Japan
Prior art keywords
alkyl
group
haloalkyl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530306A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006772 external-priority patent/WO2007109211A2/en
Publication of JP2009530306A publication Critical patent/JP2009530306A/ja
Publication of JP2009530306A5 publication Critical patent/JP2009530306A5/ja
Pending legal-status Critical Current

Links

JP2009500525A 2006-03-17 2007-03-16 脊髄性筋萎縮症の治療およびその他用途のための化合物 Pending JP2009530306A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78329206P 2006-03-17 2006-03-17
PCT/US2007/006772 WO2007109211A2 (en) 2006-03-17 2007-03-16 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013004082A Division JP2013116901A (ja) 2006-03-17 2013-01-11 脊髄性筋萎縮症の治療およびその他用途のための化合物

Publications (2)

Publication Number Publication Date
JP2009530306A JP2009530306A (ja) 2009-08-27
JP2009530306A5 true JP2009530306A5 (enExample) 2010-05-06

Family

ID=38477008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009500525A Pending JP2009530306A (ja) 2006-03-17 2007-03-16 脊髄性筋萎縮症の治療およびその他用途のための化合物
JP2013004082A Abandoned JP2013116901A (ja) 2006-03-17 2013-01-11 脊髄性筋萎縮症の治療およびその他用途のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013004082A Abandoned JP2013116901A (ja) 2006-03-17 2013-01-11 脊髄性筋萎縮症の治療およびその他用途のための化合物

Country Status (10)

Country Link
US (2) US8110681B2 (enExample)
EP (1) EP2027088A2 (enExample)
JP (2) JP2009530306A (enExample)
CN (1) CN101500995A (enExample)
AU (1) AU2007227398C1 (enExample)
BR (1) BRPI0708801A2 (enExample)
CA (1) CA2645426A1 (enExample)
IL (1) IL194153A0 (enExample)
WO (1) WO2007109211A2 (enExample)
ZA (1) ZA200807936B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573080A1 (en) 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
EA018862B1 (ru) * 2007-10-19 2013-11-29 Янссен Фармацевтика, Н.В. МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びppar活性化剤
US8722723B2 (en) 2008-02-28 2014-05-13 Research Foundation Itsuu Laboratory Aromatic amide derivative
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8986935B2 (en) * 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
EP3309152B1 (en) * 2009-12-22 2020-09-09 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013062028A1 (ja) * 2011-10-25 2013-05-02 塩野義製薬株式会社 Hiv複製阻害剤
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
ES2697174T3 (es) * 2012-02-10 2019-01-22 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
WO2014012050A2 (en) * 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
EP2921480B1 (en) * 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2014102778A2 (en) * 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN105801556A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3322699B1 (en) * 2015-07-14 2019-05-15 H. Hoffnabb-La Roche Ag 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
KR20220100719A (ko) 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
AU2020319168B2 (en) 2019-07-25 2024-02-29 Novartis Ag Regulatable expression systems
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
US20240076291A1 (en) * 2020-11-24 2024-03-07 Merck Sharp & Dohme Llc Modified isoindolinones as glucosylceramide synthase inhibitors
CN115141097A (zh) * 2022-06-27 2022-10-04 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统
CN115304472A (zh) * 2022-06-27 2022-11-08 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法
KR102883783B1 (ko) * 2022-12-15 2025-11-12 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 제조방법
KR102597093B1 (ko) * 2023-06-07 2023-11-03 옙바이오 주식회사 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도
CN117740969B (zh) * 2023-11-30 2025-01-10 杭州志呈科技有限公司 一种吲哚布芬杂质检测方法及其应用
CN120965663A (zh) * 2024-05-17 2025-11-18 北京理工大学 sEH抑制剂化合物、药物组合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641040A (en) * 1968-03-27 1972-02-08 Ciba Geigy Corp Tertiary amino phenyl acetic acids
US4126691A (en) 1968-03-27 1978-11-21 Ciba-Geigy Corporation Tertiary aminoacids
DE2034240C2 (de) 1968-03-27 1982-12-02 CIBA-GEIGY AG, 4002 Basel Isoindolinderivate, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung
US3542806A (en) 1968-03-29 1970-11-24 Robins Co Inc A H 2-(1-substituted-3-pyrrolidinyl)-isoindolines
DE2046992A1 (en) * 1970-09-24 1972-03-30 Merck Patent Gmbh, 6100 Darmstadt Isoindolinophenyl-alkanoic acid esters and salts - - antiphlogistic, antipyretic and analgesic agents
DE2154525A1 (de) * 1970-11-05 1972-06-15 Carlo Erba S.P.A., Mailand (Italien) Isoindolinderivate und Verfahren zu ihrer Herstellung
FI53702C (fi) * 1971-11-22 1978-07-10 Erba Carlo Spa Foerfarande foer framstaellning av isoindolinderivat
US3890346A (en) * 1972-03-22 1975-06-17 Monsanto Co Process for the preparation of N-arylphthalimidines
GB1413173A (en) * 1972-07-07 1975-11-12 Bp Chem Int Ltd Polymerisation process
US3997669A (en) 1972-12-26 1976-12-14 Ciba-Geigy Corporation Tertiary aminoacids
JPS5233667A (en) * 1975-09-11 1977-03-14 Fuji Kagaku Kogyo Kk Process for preparation of hydrogenated 1-oxo-isoindoline derivatives
IT1113035B (it) * 1979-03-06 1986-01-20 Erba Farmitalia Esteri c alla 3 - c alla 4 aclhilici di 1-oxo-2- aperta par.graffa p aperta par. quadrata (alfa-metil) -carbossimetil chiusa par. quadrata - fenil chiusa par. graffa- isoindolina
JPS5645955A (en) 1979-09-21 1981-04-25 Hodogaya Chem Co Ltd 6-(2,3-dihydroisoindol-2-yl)fluoran compound
JPS5644686A (en) 1979-09-21 1981-04-23 Hodogaya Chem Co Ltd Pressure-sensitive reproducing paper
JPS5750960A (en) * 1980-09-10 1982-03-25 Hisamitsu Pharmaceut Co Inc Preparation of novel 4- 1-oxo-2-isoindolinyl acetophenone
JPS5845088A (ja) 1981-09-09 1983-03-16 Sumitomo Chem Co Ltd 記録紙
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
JPH03181478A (ja) 1989-12-08 1991-08-07 Banyu Pharmaceut Co Ltd ピリドンカルボン酸誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5567718A (en) 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
JP2001514655A (ja) * 1997-03-10 2001-09-11 ローマ リンダ ユニバーシティ メディカル センター アルツハイマー病予防へのr−nsaid’sの利用
AR021968A1 (es) 1998-12-23 2002-09-04 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1341765A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
EP1542667B1 (en) 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2003301346A1 (en) 2002-10-17 2004-05-04 The Trustees Of The University Of Pennsylvania Method of treating neurological diseases and disorders
WO2004048332A1 (ja) 2002-11-26 2004-06-10 Maruishi Pharmaceutical Co., Ltd. イソインドリン誘導体
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2006050451A2 (en) 2004-11-02 2006-05-11 Whitehead Institute For Biomedical Research Methods and compositions to treat motor neuron disease
ES2393800T3 (es) 2006-02-03 2012-12-28 Glaxo Group Limited Derivados de benzoisoindol para el tratamiento del dolor
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors

Similar Documents

Publication Publication Date Title
JP2012510502A5 (enExample)
JP2021534124A5 (enExample)
JP2014051526A5 (enExample)
JP2007529534A5 (enExample)
JP2010504286A5 (enExample)
JP2020524719A5 (enExample)
JP2011137006A5 (enExample)
JP2007246474A5 (enExample)
JP2010509379A5 (enExample)
JP2011515483A5 (enExample)
JP2008525417A5 (enExample)
JP2013509392A5 (enExample)
JP2008528447A5 (enExample)
JP2008530099A5 (enExample)
JP2018536648A5 (enExample)
JP2012511588A5 (enExample)
CA2485926A1 (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
WO2007001975A8 (en) Piperidine derivatives useful as histamine h3 antagonists
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
JP2007532627A5 (enExample)
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
JP2022533939A5 (enExample)
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
JP2017538773A5 (enExample)
JP2008517020A5 (enExample)